Of these 173 patients, 87 were randomized to the glyburide group (Fig 1): 4 patients were excluded from the trial (type 2 diabetes, pharmacotherapy unnecessary, lost to follow-up, treatment refused), and 18 patients were switched to insulin treatment due to inadequate blood glucose control. The gene discussed is INS; the disease is type 2 diabetes mellitus.